MetLife director adds 687 shares via dividend reinvestment
MetLife, Inc. reported that one of its directors acquired additional common stock through a routine plan-related transaction.
Rhea-AI Filing Summary
MetLife, Inc. reported that one of its directors acquired additional common stock through a routine plan-related transaction. On 12/09/2025, the director obtained 687 shares of MetLife common stock at $77.82 per share, described as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 102,754 shares of MetLife common stock in direct form.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 687 | $77.82 | $53K |
Footnotes (1)
- F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
FAQ
What insider transaction did MetLife (MET) report in this Form 4?
The filing shows a MetLife director acquired 687 shares of MetLife common stock on 12/09/2025 at $77.82 per share.
What is the relationship of the reporting person to MetLife (MET)?
The reporting person is identified as a Director of MetLife, Inc. on the form.
Does this MetLife (MET) Form 4 involve derivative securities?
No derivative securities are reported in Table II; the only reported transaction involves MetLife common stock in Table I.
AI-generated analysis. How Rhea-AI works. Not financial advice.